Prognostic Value of Metabolic Activity Measured by 18F-FDG PET/CT in Patients with Advanced Endometrial Cancer

被引：9

作者：

Kim H.J. ^{[1
]}

Choi J. ^{[1
]}

Jeong Y.H. ^{[1
]}

Jo K.H. ^{[1
]}

Lee J.-H. ^{[1
]}

Cho A. ^{[1
]}

Yun M. ^{[1
]}

Lee J.D. ^{[1
]}

Kim Y.T. ^{[2
]}

Kang W.J. ^{[1
]}

机构：

[1] Department of Nuclear Medicine, Yonsei University College of Medicine, Seoul, 120-752, 134 Shinchon-dong, Seodaemoon-gu

[2] Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul

来源：

Nuclear Medicine and Molecular Imaging | 2013年 / 47卷 / 4期

关键词：

Endometrial cancer; Fluorodeoxyglucose; PET; Prognosis;

D O I：

10.1007/s13139-013-0228-2

中图分类号：

学科分类号：

摘要：

Purpose: We evaluated the potential prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with stage IIIC/IV endometrial cancer. Methods: Patients with stage IIIC/IV endometrial cancer who had undergone FDG PET/CT workup for staging were enrolled. Maximum standardized uptake values (SUVmax) measured from regions of interest (ROIs) of the primary tumor (SUVt) and lymph nodes (SUVn) were correlated with overall survival (OS). The SUVn was defined as the highest SUVmax of the metastatic lymph nodes. Survival probability was assessed using the Kaplan-Meier method. Results: A total of 42 patients with a median age of 55.5 years (range 32-76 years) were included. Twenty-nine percent (n = 12) of patients were premenopausal and 71 % (n = 30) were postmenopausal. The average SUVt was 12.9 (range 1.8-36.5), and the average SUVn was 7.3 (range 2.0-22.5). Median follow-up time was 25.9 months (range 1-84 months). Using a SUVt of 9.5 as a cutoff value, two groups with different rates were determined (P = 0.026). In addition, patients with a low SUVn had significantly better OS than those with a high SUVn (P = 0.003). Patients in the International Federation of Obstetrics and Gynecology (FIGO) stage IV group with SUVt ≥ 9.5 or SUVn ≥ 7.3 showed a significantly longer OS than the other groups. Conclusions: FDG uptake of primary endometrial cancer and lymph nodes might be a prognostic factor in advanced endometrial cancer. More aggressive therapy could be considered in patients with stage IV endometrial cancer and high SUVt and/or high SUVn. © 2013 Korean Society of Nuclear Medicine.

引用

页码：257 / 262

页数：5

共 26 条

[1]

Amant F., Moerman P., Neven P., Timmerman D., van Limbergen E., Vergote I., Endometrial cancer, Lancet, 366, pp. 491-505, (2005)

[2]

Parkin D.M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002, CA Cancer J Clin, 55, pp. 74-108, (2005)

[3]

Rose P.G., Endometrial carcinoma, N Engl J Med, 335, pp. 640-649, (1996)

[4]

Trope C.G., Alektiar K.M., Sabbatini P.J., Et al., Corpus: epithelial tumors, In: Principles and practice of gynecologic oncology, (2005)

[5]

Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., Heller P.B., Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study, Cancer, 60, pp. 2035-2041, (1987)

[6]

Wong R.J., Lin D.T., Schoder H., Patel S.G., Gonen M., Wolden S., Et al., Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma, J Clin Oncol, 20, pp. 4199-4208, (2002)

[7]

Minn H., Lapela M., Klemi P.J., Grenman R., Leskinen S., Lindholm P., Et al., Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer, J Nucl Med, 38, pp. 1907-1911, (1997)

[8]

Allal A.S., Dulguerov P., Allaoua M., Haenggeli C.A., el El-Ghazi A., Lehmann W., Et al., Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy, J Clin Oncol, 20, pp. 1398-1404, (2002)

[9]

Casasnovas R.O., Meignan M., Berriolo-Riedinger A., Bardet S., Julian A., Thieblemont C., Et al., SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma, Blood, 118, pp. 37-43, (2011)

[10]

Itti E., Lin C., Dupuis J., Paone G., Capacchione D., Rahmouni A., Et al., Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy, J Nucl Med, 50, pp. 527-533, (2009)

← 1 2 3 →